GLP-1r

Reed, Joshua; Kanamarlapudi, Venkateswarlu

doi:10.1007/978-3-319-67199-4_101967

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This figure and information in its legend are with data adapted from these studies. 94 , 105 , 106 , 111 , 192–195 , 206 , 214 , 219–222 , 225 , 228 , 232 , 241 , 326–328 , 331 …”

Section: Extrapancreatic Tissues Involvement In T2d: Aetiology/pathogenesis and Post-diagnosis Complicationsmentioning

confidence: 99%

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives

Reed¹,

Bain²,

Kanamarlapudi³

2021

DMSO

Self Cite

237

124

View full text Add to dashboard Cite

Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.

show abstract

“…This figure and information in its legend are with data adapted from these studies. 94 , 105 , 106 , 111 , 192–195 , 206 , 214 , 219–222 , 225 , 228 , 232 , 241 , 326–328 , 331 …”

Section: Extrapancreatic Tissues Involvement In T2d: Aetiology/pathogenesis and Post-diagnosis Complicationsmentioning

confidence: 99%